Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $751,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Key Points

• Empirical Financial Services LLC increased its stake in Amneal Pharmaceuticals by 93.8%, now holding 89,598 shares valued at approximately $751,000.
• Over 31% of Amneal Pharmaceuticals' stock is owned by institutional investors, indicating strong interest from larger financial entities.
• Amneal Pharmaceuticals reported earnings of $0.19 EPS for the last quarter, exceeding analysts' expectations of $0.14 EPS.

Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 93.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 89,598 shares of the company's stock after acquiring an additional 43,358 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management's holdings in Amneal Pharmaceuticals were worth $751,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Amalgamated Bank boosted its position in shares of Amneal Pharmaceuticals by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock valued at $46,000 after buying an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. boosted its holdings in Amneal Pharmaceuticals by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 7,934 shares of the company's stock worth $66,000 after acquiring an additional 1,428 shares during the last quarter. Xponance Inc. raised its holdings in shares of Amneal Pharmaceuticals by 16.1% in the first quarter. Xponance Inc. now owns 13,183 shares of the company's stock valued at $110,000 after purchasing an additional 1,828 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Amneal Pharmaceuticals by 2.5% during the fourth quarter. MetLife Investment Management LLC now owns 94,639 shares of the company's stock worth $750,000 after purchasing an additional 2,297 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Amneal Pharmaceuticals by 3.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 90,460 shares of the company's stock valued at $716,000 after buying an additional 2,911 shares during the last quarter. 31.82% of the stock is owned by institutional investors.

Amneal Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ AMRX opened at $7.83 on Friday. The business has a 50-day moving average of $7.94 and a 200-day moving average of $7.96. The firm has a market capitalization of $2.45 billion, a price-to-earnings ratio of -195.70 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a 12 month low of $6.50 and a 12 month high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. The firm had revenue of $695.42 million for the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative net margin of 0.46% and a negative return on equity of 188.26%. On average, analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on AMRX. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $11.60.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.